Revance Therapeutics Inc

NASDAQ:RVNC  
14.01
+1.30 (+10.28%)
4:35:37 PM EDT: $14.00 -0.01 (-0.04%)
Earnings Announcements

Revance Reports Q1 2022 Financial Results

Published: 05/10/2022 21:21 GMT
Revance Therapeutics Inc (RVNC) - Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update.
Revance Therapeutics - Revenue for Q1 Ended March 31, 2022 Was $25.3 Million, Representing an Increase of 89.9% From $13.3 Million in Same Period in 2021.
Qtrly Basic and Diluted Net Loss per Share $0.94.
Q1 Earnings per Share View $-0.91, Revenue View $24.0 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $27.98 Million
Adjusted EPS is expected to be -$0.81

Next Quarter Revenue Guidance is expected to be $28.25 Million
Next Quarter EPS Guidance is expected to be -$0.83

More details on our Analysts Page.